Bridgewater Chapter Upcoming Events Join PCCI

PCCI of New Jersey

It’s where top-tier industry experts meet each month to help up-and-coming life sciences start-ups.

 

SEE BELOW for details of the upcoming meeting.

 

PCCI provides complimentary executive level consulting services to help early-stage life sciences companies succeed.  We provide our members and their guest with an informal networking venue supporting our mission to help Pharma start-up companies move forward and to facilitate and create business opportunities for PCCI members and their guests.

 

Tapping the vast talent pool of highly skilled pharma and medical device executives provides the New Jersey Chapter membership with direct access to over 300 experts.

 

Great venue, knowledge & networking!

 

Become a Member of
PCCI New Jersey

If you haven’t joined yet, then join today. 
Life time memberships are only $150.00.  

 

Use Paypal or Credit Card to become a member online instantly.

 

 

Our Sponsors

EisnerAmper

 

 

Our Next Meeting

Intrommune Therapeutics

A biotechnology company developing patient-friendly therapies for the treatment of food allergies

Presenter: Michael D. Nelson

Monday, June 10, 2019

Norris McLaughlin P.A. (directions)

400 Crossing Boulevard, 8th Floor, Bridgewater, NJ 08807

About

 

Intrommune Therapeutics is a biotechnology company developing patient-friendly therapies for the treatment of food allergies. The company’s oral mucosal therapeutic platform is based on the well-accepted principles of allergy immunotherapy. Immunotherapeutic agents are regularly administered to areas of the oral cavity with the highest likelihood of decreasing allergy symptoms, gradually desensitizing the immune system to specific foods.

 

Technology

  • Oral mucosal immunotherapy (OMIT) is administered via a specially formulated toothpaste that incorporates and stabilizes allergens (food proteins)
  • Toothbrushing brings allergens into contact with specialized immune cells throughout the oral cavity

 

Platform Advantages

  • Completed proof-of-concept clinical investigation validates OMIT approach
  • Published study data consistent with safety and adherence advantages over other allergy immunotherapies-Global IP portfolio protects OMIT products at least through 2033; Five patents issued thus far; global prosecution ongoing

 

Product Pipeline

  • Lead product is INT301 for treating peanut allergy
  • INT301’s efficacy is driven by (1) OMIT’s optimization of administration and (2) integration into daily tooth brushing routine for consistent, long-term adherence
  • Pre-IND meeting completed July 2018; Agency agrees with company plans for
    • IND submission material
    • Phase Ib study plans with an abbreviated up-dosing regimen
  • Follow-on products will treat other common food allergies such as egg, milk, and tree nuts

 

Market

  • Over 3 million people (including 1.5 million children) in the US suffer from peanut allergy at a cost in excess of $6 billion annually
  • There is currently no approved treatment for any food allergy other than strict avoidance

 

 

Questions for Discussion

 

  1. Manufacturing/CMC  - particularly assays, HPLC, consistency, lack of fungal contamination
  2. Regulatory - issues around converting a food to a pharmaceutical, potential complications if add fluoride, and
  3. Potential for grants

 

 

Program:

 

6:00 – Dinner and Drinks
7:00 – Michael D. Nelson, will deliver the company's "elevator" pitch to the group

8:00 – Q&A Session

9:00 – Networking

 

 

<Top of the page>

 

 


Reservation

 

Reserve your dinner for this month's meeting online now though PayPal.

Please note: You do not need a PayPal account to reserve your spot, most credit cards are accepted.

 

 

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

None available at this time

Contact Info:

 

 

 

 

Questions or Coments?

Contact: David S. Blatteis

david@rxpcci.com | (908) 252-4233

 

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   DIRECTIONS  |   BRIDGEWATER DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES

PROFILES CALENDAR OF EVENTS  |  BRIDGEWATER CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018

 

 

Tat Communication Inc